Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
GLMD
GLMD
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GLMD News
Galmed Pharmaceuticals Achieves Major Milestone with AM-001 Study Results
May 14 2026
PRnewswire
Development of Novel Cardiac Fibrosis Model Announced
May 06 2026
PRnewswire
Tissue Dynamics and Galmed Collaborate on Cardiac Fibrosis Model Development
May 06 2026
Newsfilter
Galmed Partners with Tel Aviv University to Develop New Therapy
Apr 15 2026
NASDAQ.COM
Galmed Partners with Tel Aviv University to Develop New Cancer Therapy
Apr 14 2026
PRnewswire
Galmed Partners with Tel Aviv University to Develop Aramchol for Brain Metastases
Apr 14 2026
Newsfilter
Galmed Pharmaceuticals Shares Surge 85% on New Drug Formulation Launch
Apr 09 2026
stocktwits
Galmed Pharmaceuticals Announces Breakthrough in CNS Drug Development
Apr 09 2026
PRnewswire
Galmed Develops New Aramchol Formulation for CNS Diseases
Apr 09 2026
Newsfilter
GALMED PHARMACEUTICALS LTD CREATES BRAIN-PENETRATING ARAMCHOL FORMULATION USING BARCODE NANOTECHNOLOGY
Apr 09 2026
moomoo
Galmed Pharmaceuticals Receives Nasdaq Compliance Notice
Jan 30 2026
seekingalpha
Galmed Pharmaceuticals Receives Nasdaq Compliance Notice
Jan 30 2026
PRnewswire
Galmed Pharmaceuticals Faces Nasdaq Compliance Challenge
Jan 30 2026
Newsfilter
Galmed Pharmaceuticals to Initiate Phase 1/2 Trial of Aramchol and Regorafenib in 2026
Dec 08 2025
PRnewswire
Galimedix Reports Excellent Phase 1 Results for GAL-101 with No Adverse Events
Dec 04 2025
Globenewswire
Galmed Secures New Patent for Aramchol, Extending Protection to 2042
Dec 04 2025
PRnewswire
Show More News
